Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Stingray Declares Quarterly Dividend to Shareholders
-
Petrus Resources Announces Fourth Quarter and Year-End 2024 Financial, Operating & Reserves Results
-
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
-
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
-
Navigator Gas Announces Availability of its Annual Report on Form 20-F for the Year Ended December 31, 2024
-
Rogers Communications 1Q25 Investment Community Teleconference April 23, 2025 at 8:00 a.m. ET
-
HII’s Ingalls Shipbuilding Launches Guided Missile Destroyer Future USS Jeremiah Denton (DDG 129)
-
Genmab Announces Initiation of Share Buy-Back Program
-
Hammond Power Solutions Announces Lead Director Retirement
-
Optiva Inc. Reports Fourth Quarter 2024 Financial Results
-
AirJoule Technologies Announces Fourth Quarter and Full Year 2024 Results and Groundbreaking Performance of AirJoule® System
-
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
-
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
-
CAPREIT Announces Timing of First Quarter 2025 Results & Conference Call
-
ERES Announces Timing of First Quarter 2025 Results & Conference Call
-
Saturn Oil & Gas Inc. Announces Participation in Virtual Investor Conference on March 27th
-
Weatherford Releases 2024 Digital Annual Update
-
Element Nominates Paolo Ferrari and Tracey McVicar for Election to the Board of Directors
-
Saturn Oil & Gas Inc. Announces Participation in Virtual Investor Conference on March 27th
-
Bombardier Defense Announces Order of Two Challenger 650 Aircraft Destined for Intelligence, Surveillance and Reconnaissance missions in Australia
-
CISO Global Announces Pay Off of Highest-Interest Debt, Extends $7M in Convertible Notes
-
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
-
W&T Offshore Announces Management Promotion
-
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
-
Freddie Mac Issues Monthly Volume Summary for February 2025
-
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
-
True North Mortgage Welcomes 25+ Former Rocket Mortgage Canada Employees, Expands Windsor and Quebec Presence
-
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
-
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
-
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
-
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
-
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
-
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
-
Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting
-
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
-
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market
-
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
-
Nouscom to Present Final Results from Successful Phase Ib/II Trial of NOUS-209 in People Living with Lynch Syndrome, Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Deve
-
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
-
Farmers & Merchants Bancorp, Inc. Declares 2025 First-Quarter Cash Dividend
-
Media Advisory — Newport News Shipbuilding Apprentice School to Host Commencement Ceremony for 2024 Graduates
-
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
-
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
-
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
-
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
-
ECD Auto Design Reports Third Quarter 2024 Financial Results; Revenues Increase 30% to $6.4 Million
-
CLEAR and American Express Renew Partnership to Provide Premium Travel Experiences at Airports to Card Members
-
Farmers & Merchants Bancorp, Inc. Declares 2025 First-Quarter Cash Dividend
-
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual M
-
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
